This company has been marked as potentially delisted and may not be actively trading. NASDAQ:SONN Sonnet BioTherapeutics (SONN) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Sonnet BioTherapeutics Stock (NASDAQ:SONN) Get Sonnet BioTherapeutics alerts:Sign Up Key Stats Today's Range$1.26▼$3.2350-Day Range$1.02▼$5.9252-Week Range$1.08▼$19.30Volume10.08 million shsAverage Volume2.09 million shsMarket Capitalization$7.18 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Sonnet BioTherapeutics Holdings, Inc. is a clinical-stage biotechnology company dedicated to developing innovative cytokine-based therapeutics for oncology and autoimmune disorders. The company’s platform centers on engineering human cytokines, notably interleukin-2 and related molecules, fused to carrier proteins such as human serum albumin. This design aims to extend circulating half-life, enhance tumor localization, and minimize systemic toxicity compared with traditional cytokine therapies. Sonnet’s lead pipeline candidates are in early-phase clinical trials for the treatment of solid tumors, where the company seeks to demonstrate improved efficacy and safety. In parallel, Sonnet is advancing preclinical immunocytokine programs targeting specific aspects of the tumor microenvironment to further leverage its fusion protein technology across multiple cancer indications. Headquartered in San Diego, California, Sonnet BioTherapeutics conducts research and development operations in the United States. The management team comprises seasoned industry professionals with expertise in immuno-oncology, biologics development, and clinical strategy, positioning the company to progress its pipeline toward later-stage trials and potential partnerships.AI Generated. May Contain Errors. Read More Sonnet BioTherapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks0th Percentile Overall ScoreSONN MarketRank™: Sonnet BioTherapeutics scored higher than 0% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.5 / 5Analyst RatingSell Consensus RatingSonnet BioTherapeutics has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageSonnet BioTherapeutics has received no research coverage in the past 90 days.Read more about Sonnet BioTherapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Sonnet BioTherapeutics is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sonnet BioTherapeutics is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for SONN. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSonnet BioTherapeutics does not currently pay a dividend.Dividend GrowthSonnet BioTherapeutics does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A Search Interest1 people have searched for SONN on MarketBeat in the last 30 days. Company Ownership0.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Sonnet BioTherapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders8.48% of the stock of Sonnet BioTherapeutics is held by insiders.Percentage Held by Institutions9.45% of the stock of Sonnet BioTherapeutics is held by institutions.Read more about Sonnet BioTherapeutics' insider trading history. Receive SONN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sonnet BioTherapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SONN Stock News HeadlinesHyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business CombinationDecember 2, 2025 | globenewswire.comSonnet BioTherapeutics stockholders approve Hyperliquid Strategies combinationDecember 2, 2025 | msn.comThe cat is out the bagAlmost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered separation packages to 8,500 workers, and Oracle is reportedly eliminating up to 30,000 positions. Goldman Sachs estimates 12,400 Americans are being financially displaced every single day. Analyst Porter Stansberry says the real driver runs deeper than AI - and two Nobel Prize winners have issued the same warning. He calls it the Final Displacement, and he's releasing a full investigation with specific companies to buy and sell before the next wave hits.August 18 at 1:00 AM | Porter & Company (Ad)Sonnet BioTherapeutics Holdings, Inc. Announces Stockholder Approval of Proposed Business Combination with Hyperliquid Strategies IncDecember 2, 2025 | finance.yahoo.comSonnet BioTherapeutics Holdings, Inc. Announces Adjournment of Special MeetingNovember 18, 2025 | globenewswire.comSonnet BioTherapeutics Announces Special Meeting for Business Combination VoteOctober 29, 2025 | msn.comHyperliquid’s HYPE soars as Wall Street backs $888 million mergerOctober 23, 2025 | msn.comHyperliquid Wants $1B to Power Its Next HYPE Token ExpansionOctober 23, 2025 | finance.yahoo.comSee More Headlines SONN Stock Analysis - Frequently Asked Questions How were Sonnet BioTherapeutics' earnings last quarter? Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) issued its earnings results on Wednesday, August, 13th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.49) by $0.46. When did Sonnet BioTherapeutics' stock split? Shares of Sonnet BioTherapeutics reverse split on the morning of Sunday, September 29th 2024.The 1-8 reverse split was announced on Sunday, September 29th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Sunday, September 29th 2024. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split. What other stocks do shareholders of Sonnet BioTherapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Sonnet BioTherapeutics investors own include Plug Power (PLUG), SNDL (SNDL), NIO (NIO), Zomedica (ZOM), VYNE Therapeutics (VYNE), Avino Silver & Gold Mines (ASM) and Dare Bioscience (DARE). Company Calendar Last Earnings8/13/2025Today8/18/2026Fiscal Year End9/30/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:SONN CIK1106838 Webwww.chanticleerholdings.com Phone609-375-2227Fax704-366-2463Employees10Year Founded2011Profitability EPS (Trailing Twelve Months)($8.05) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$7.44 million Net MarginsN/A Pretax Margin-1,339.60% Return on Equity-4,646.10% Return on Assets-342.21% Debt Debt-to-Equity RatioN/A Current Ratio0.26 Quick Ratio0.26 Sales & Book Value Annual Sales$1 million Price / Sales7.18 Cash FlowN/A Price / Cash FlowN/A Book Value($0.71) per share Price / Book-1.43Miscellaneous Outstanding Shares7,078,000Free Float6,478,000Market Cap$7.18 million OptionableNot Optionable Beta1.48 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:SONN) was last updated on 8/18/2026 by MarketBeat.com Staff. From Our PartnersElon's Terrifying Warning: America Is "1,000% Going Bankrupt"The national debt just crossed $39 trillion, and Elon Musk - former head of the Department of Government Effic...American Hartford Gold | SponsoredThree oil giants buried the same discovery for 50 yearsIn 1976, Chevron tapped an energy source with no fuel costs, no carbon, and no supply chain - then killed the ...Behind the Markets | SponsoredIran War: What Happened at 1:11 P.M. Outside D.C.?A source with ties to Saudi Arabia, the UAE, and the U.S. State Department revealed details of a potential 7 t...Banyan Hill Publishing | SponsoredTrump’s New Currency ResetTrump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...Porter & Company | Sponsored19 Factories. One AI Brain. One Hidden Stock.A little-known aerospace manufacturer has linked 19 factories worldwide into a single AI-ready data system, dr...The Oxford Club | SponsoredA Dark Day Is Coming to AmericaKeith Kaplan, CEO of TradeSmith, has spent more than $17 million studying AI since 2022. He says a major shift...TradeSmith | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredYour withdrawal order could cost you in taxesIf you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...SmartAsset | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sonnet BioTherapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sonnet BioTherapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
